Orphazyme A/S
Investor news
No. 04/2018
Copenhagen, March 9, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co. 38th Annual Health Care Conference in Boston, Massachusetts, USA on March 12, 2018 at 2:10-2:40 PM EST.
About Orphazyme A/S
Orphazyme is a Danish biopharmaceutical company focused on the development of treatments for patients living with life-threatening or debilitating rare diseases. Our research is concentrated on the cell-protective properties of the body’s own rescue system for diseases caused by misfolded proteins or lysosomal dysfunction. The company’s lead candidate, arimoclomol, is in development for four severe orphan diseases; two muscle-wasting diseases, sporadic Inclusion Body Myositis (sIBM) and Amyotrophic Lateral Sclerosis (ALS), and two lysosomal storage diseases, Niemann-Pick disease Type C (NPC) and Gaucher disease. We are listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
03-2018 Orphazyme to Present at Cowen & Co. 38th Annual Health Care Conference
